River Global Investors’s United Therapeutics UTHR Stock Holding History

River Global Investors’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-7,000	Closed	-$792K	–	126
2018 Q2	$792K	Hold	7,000	–	–	0.08%	120
2018 Q1	$786K	Hold	7,000	–	–	0.09%	118
2017 Q4	$1.04M	Hold	7,000	–	–	0.12%	108
2017 Q3	$820K	Hold	7,000	–	–	0.12%	103
2017 Q2	$908K	Buy	+7,000	New	+$873K	0.17%	94
2016 Q3	–	Sell	-775	Closed	-$82K	–	128
2016 Q2	$82K	Buy	775 +350	+82%	+$39K	0.04%	96
2016 Q1	$47K	Buy	425 +125	+42%	+$15.8K	0.03%	113
2015 Q4	$46K	Buy	+300	New	+$43.7K	0.03%	90

Other funds holding UTHR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

River Global Investors's UTHR Position: Q3 2018 in Review

River Global Investors sold out of United Therapeutics (UTHR) in Q3 2018, closing a stake of 7,000 shares — an estimated $792K sold.

River Global Investors first reported a position in UTHR in Q4 2015 and held it in 8 quarters. The position peaked at $1.04M in Q4 2017. 367 funds tracked by Wall St. Rank hold UTHR as of Q3 2018.

River Global Investors reported no remaining United Therapeutics position as of Q3 2018 after selling out during the quarter.
River Global Investors sold 7,000 United Therapeutics shares in Q3 2018, an estimated $792K.
River Global Investors first reported a position in United Therapeutics in Q4 2015 and held it in 8 quarters.
River Global Investors's United Therapeutics position peaked at $1.04M in Q4 2017.
367 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2018.

Based on River Global Investors's 13F filing for Q3 2018, filed 14 Nov 2018.